BioPharm Brief: RNAi, Obesity, and Diabetes Advances

Why It Matters

The financing fuels rapid RNAi development, while the positive Phase 3 data expand therapeutic options for obesity, liver disease, and type 2 diabetes, potentially reshaping treatment algorithms and market dynamics.

Key Takeaways

• City Therapeutics raises $99.5M Series B for next‑gen RNAi
• CITY‑FXI launches Phase 1 for thromboembolic disease
• Survodutide cuts visceral and liver fat in Phase 3
• Foundayo beats oral semaglutide on A1C and weight

Pulse Analysis

The infusion of $99.5 million into City Therapeutics underscores a growing investor appetite for RNA interference technologies that promise precise gene silencing. By advancing CITY‑FXI into Phase 1 and positioning a Stargardt disease candidate for clinical entry, the company aims to validate a platform that could accelerate the pipeline of rare‑disease and cardiovascular therapies, challenging incumbents that rely on traditional biologics.

In parallel, the dual‑agonist survodutide delivers compelling evidence that targeting both glucagon and GLP‑1 receptors can address the twin burdens of obesity and metabolic‑dysfunction‑associated steatotic liver disease (MASLD). The Phase 3 reductions in visceral adipose tissue and hepatic fat suggest a disease‑modifying effect beyond weight loss, positioning the drug as a potential first‑in‑class option for patients at high cardiometabolic risk and opening new reimbursement pathways for liver‑focused indications.

Eli Lilly’s oral GLP‑1 candidate Foundayo marks a watershed moment for oral peptide therapeutics. By surpassing oral semaglutide in A1C reduction and weight loss, it validates the feasibility of non‑injectable GLP‑1 delivery, a long‑sought goal that could broaden patient adherence and capture market share from injectable competitors. With multiple Phase 3 programs nearing FDA submission, Foundayo could catalyze a shift toward oral regimens in type 2 diabetes, prompting competitors to accelerate their own oral pipelines and reshaping the competitive landscape.